FDA & Government News

July 13, 2026

FDA Approves At-Home Starting Dose for Lecanemab

Patients may begin lecanemab-irmb treatment at home through self-administration or administration by a caregiver, according to the FDA.

Conexiant

July 07, 2026

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

Conexiant

June 29, 2026

Parkinson Mortality Rate Was 72 per 100,000 in 2024

The age-adjusted Parkinson disease death rate among US adults aged 65 years and older was 72.0 deaths per 100,000 standard population in 2024, lower than the 2021 rate, according to a National Center for Health Statistics Data Brief.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

June 08, 2026

Aid in Dying Nears One Third of US

New laws in New York and Illinois will soon make medical aid in dying available to nearly one-third of Americans.

Kff Health News

June 04, 2026

HHS Seeks Broader Access to Health Data

"We can’t do anything our agreements don’t allow us to do"

Kff Health News

May 11, 2026

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

Conexiant

May 05, 2026

Prescribing Outside the Exam Room

A DEA case exposes how controlled substances can move outside clinical oversight.

Conexiant

April 30, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

Conexiant

Head-to-Head Trial in Relapsing MS

FDA & Government News

FDA Approves At-Home Starting Dose for Lecanemab

Head-to-Head Trial in Relapsing MS

Parkinson Mortality Rate Was 72 per 100,000 in 2024

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

When Bad Data Enters the Drug Pipeline

Daily News

Aid in Dying Nears One Third of US

HHS Seeks Broader Access to Health Data

New Label Expansion in Generalized Myasthenia Gravis

Prescribing Outside the Exam Room

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Head-to-Head Trial in Relapsing MS

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

Conexiant

AACE Endocrinology AI

Conexiant

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

FDA & Government News

Daily News

Recommendations